News | EP Mapping and Imaging Systems | October 15, 2019

Kardium Announces Successful Results From GLOBAL-AF Study

Patients treated with Globe electrophysiology mapping and ablation solution showed 76 percent freedom from atrial fibrillation at 12 months after single treatment

Kardium Announces Successful Results From GLOBAL-AF Study

October 15, 2019 — Kardium Inc. announced that the Globe mapping and ablation system has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology.[1] The study demonstrated a 76 percent percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe system.

“I am very excited about the results from this first clinical experience with the Globe system” said Prof. Hans Kottkamp, head of electrophysiology, Sana Hospitals, Düsseldorf, Germany, the principal investigator. “The Globe system has demonstrated the ability to provide rapid and effective pulmonary vein isolation. In addition, the ability to perform high-resolution mapping and ablation of the atrium will deliver a unique and comprehensive treatment for patients that has the potential to further improve outcomes and advance new strategies for the treatment of AF.”

The Globe system is a mapping and ablation solution that consists of a catheter with 122 electrodes and advanced software, that together enable rapid pulmonary vein isolation, high-resolution mapping and the ability to ablate anywhere in the atrium, all with a single catheter.

Atrial fibrillation is the most common heart rhythm disorder and affects about 33 million people worldwide. It can increase the risk of stroke by up to five times.

The GLOBAL-AF study is a prospective multicenter study that evaluated the safety and effectiveness of the system in 60 patients at two centers in Europe. Patients were assessed for atrial fibrillation with seven-day continuous Holter monitoring at discharge and then 3, 6 and 12 months after the treatment. Patients in the efficacy cohort had 100 percent pulmonary vein isolation and 76 percent freedom from atrial fibrillation at 12 months, off antiarrhythmic drugs, after a single procedure.

For more information: www.kardium.com

Reference

1. Kottkamp H., Hindricks G., Ponisch C., et al. Global multielectrode contact‐mapping plus ablation with a single catheter in patients with atrial fibrillation: Global AF study. Journal of Cardiovascular Electrophysiology, published online Sept. 11, 2019. https://doi.org/10.1111/jce.14172


Related Content

News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
News | Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home December 22, 2023
Home
News | Atrial Fibrillation

December 14, 2023 — Medtronic plc, a global leader in healthcare technology, today announced that the United States Food ...

Home December 14, 2023
Home
News | Atrial Fibrillation

December 13, 2023 — A new artificial intelligence (AI) model designed by Scripps Research scientists could help ...

Home December 13, 2023
Home
News | Atrial Fibrillation

December 8, 2023 — The American College of Cardiology (ACC) and the American Heart Association (AHA), along with several ...

Home December 08, 2023
Home
News | Atrial Fibrillation

December 7, 2023 — Ajax Health announced today the formation and funding of Cortex, a medical technology company ...

Home December 07, 2023
Home
Subscribe Now